|   In the News

Generation Bio snaps up Boston area plant as it rolls out a manufacturing process it thinks will be a game changer

Generation Bio is looking to move the field of gene therapy into the future, and thinks it has a manufacturing process in place that will allow enough scale for broad disease indications. Now, all it needs is a plant to put those large-scale ambitions into action.

Read more.


  |   From the Trenches

Immuno-Oncology: The Comeback Kid

Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011 and the seminal initial efficacy disclosure on nivolumab (anti-PD1) in 2012 (Topalian et al NEJM), we can reflect on how I-O has literally changed the lives of tens of thousands of cancer patients and their families.

By Tim Reilly & Jonathan Montagu, CDO and CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC

Read more.


  |   Press Release

Atlas Venture Welcomes Jodie Morrison as Venture Partner

Atlas Venture, a leading early stage venture capital firm, announced today that Jodie Morrison is joining the firm as a venture partner. Jodie will work with the Atlas team to build transformative new biotech companies.

Read more.


  |   From the Trenches

SPAC downpour continues

Holy cow, have we seen the rain lately – both downpours outside and a downpour of SPAC activity.

By Sam Truex, Venture Partner at Atlas Venture, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Playing To Win: Building A Position Of Strength In Biotech

When I play board games, I play to win. That requires thinking several moves ahead. In the game Risk, for instance, it’s not enough to just conquer Australia. If you want to use the continent as a launch pad to take over the world, you need to design and execute on a long-term strategy.

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC

Read more.